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In February 2010, Shahid Beheshti University of 
Medical Sciences (SBUMS) organised in Tehran 
a very high standard conference on ocular 
inflammation and uveitis. Several members 
of the executive committee of the Society for 
Ophthalmo-Immunoinfectiology in Europe 
(SOIE) took active part in that meeting and we 
thoroughly enjoyed the superb hospitality given 
to us by our Iranian colleagues. After 3 days of 
friendly contacts, stimulating exchanges and 
mutual convergence of opinions and interests, 
the idea emerged to work on one issue of 
Journal of Ophthalmic and Vision Research 
(JOVR) devoted to uveitis and inflammatory 
eye diseases. This partnership between the 
SOIE and SBUMS led to the project resulting 
today and publication of the present issue. Such 
collaborative work, building bridges between 
clinicians and researchers from different parts of 
the world, corresponds exactly to the philosophy 
of the SOIE, a society dedicated to teaching and 
promotion of knowledge in the field of uveitis 
and inflammatory eye diseases in Europe and 
beyond. Since its formal foundation in 2005 in 
Lausanne, Switzerland, SOIE has organised 
courses and meetings in Monte Carlo, Monaco 
in 2006, Krakow, Poland in 2007, Cappadocia, 
Turkey in 2008, the oasis of Tozeur, Tunisia in 
2009, St. Petersburg, Russia in 2010, Bad Blumau, 
Austria in 2011 and Vilnius, Lithuania 2011. To 
expand its range of activities, a sister society 
the Society for ophthalmo-immunoinfectiology 
in Europe and the Middle-East (SOIEME) 
was established in 2011, in order to intensify 
contacts in that part of the world, an example 
of which is the collaboration that led to the 
present achievement.
This issue was planned to include and 
combine articles by Iranian authors on one 
side and from authors in connection with the 
SOIE on the other side. After a little more than 
one year of work and efforts, we succeeded to 
build an issue consisting of 14 peer-reviewed 
articles, equally divided between contributors 
from Iran and from the SOIE. 
In this editorial, articles originating from 
the SOIE will be commented, while Professor 
Masoud Soheilian, the other guest-editor of 
this issue, will present Iranian contributions 
in his editorial.
In their original article, Papadia M and 
colleagues1 present a topic that, to the best of their 
knowledge, has never been dealt with at least in 
the last 30 years, namely the relation between 
myopia and inflammation. They describe on one 
hand myopic changes induced by inflammation 
including the myopic shift induced by sclero-
choroidal inflammation that for example can 
occur in hyperacute Vogt-Koyanagi-Harada 
(VKH) disease or more rarely, by drugs such as 
acetazolamide or sulphonamides used in some 
cases of inflammation. On the other hand, they 
expose the most common clinical entities for 
which myopia can be a predisposing factor, such 
as multifocal choroiditis (MFC) and multiple 
evanescent white dot syndrome (MEWDS). 
Fragility of the choriocapillaris might be the 
common denominator for this association, as 
they hypothesize. The importance of indocyanine 
green angiography (ICGA) for these entities is 
put forward in this article.
As an illustration to this article, Bouchenaki 
and Herbort2 report a new approach for 
management of VKH disease. Progression 
of quasi 100% of VKH cases to sunset glow 
fundus even in the absence of clinically 
apparent disease assumes silent progression 
of choroidal disease that can only be detected Editorial; Herbort
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by ICGA. This is what the authors indicate and 
they consequently decided to follow their VKH 
patients using ICGA and treat subclinical disease 
after resolution of inflammation. In patients 
treated early enough with ICGA monitoring, 
they avoided the evolution towards sunset 
glow fundus.
Three review articles on pediatric uveitis3, 
neurologic syndromes related with uveitis4, and 
biologic treatments for uveitis5 further widen 
the scope of this issue.
Pediatric uveitis is a topic that is not dealt 
with in a unanimous and consensual fashion, 
making it the subject of controversies. Ilknur 
Tugal-Tutkun, vice-president of the SOIE and one 
of the recognized uveitis specialists in Turkey, 
based her review on an extensive personal 
experience.3 Besides giving an exhaustive 
overview on childhood uveitis there are useful 
guidelines on management of pediatric cases 
indicating that corticosteroids should be replaced 
systematically by immunosuppressive treatment 
in case prolonged treatment is anticipated.
In their review on CNS diseases and uveitis, 
Allegri P, Rissotto R and colleagues4 provide 
an exhaustive account on neurologic diseases 
commonly associated with uveitis. Although 
the review is a collaborative work between a 
neurologist and ophthalmologists, the approach 
is from the neurologist’s point of view focusing 
on the neurologic side of these syndromes 
without neglecting the ophthalmological 
counterparts. This is probably interesting for 
ophthalmologists who are usually well informed 
on the ophthalmologic characteristics of these 
ocular/neurologic inflammatory concomitants 
but less so about their neurologic characteristics.
Piergiorgio Neri5, general secretary of the 
SOIE and one of the leading ocular immun-
ologists in Italy contributes a short, albeit 
practical review on biologic treatments currently 
used in the management of non-infectious 
uveitis. Besides being a systematic review, it 
is based on long-standing experience, giving 
the clinician a present-day scope on these 
new and promising, sometimes sight-saving, 
therapeutic principles.
Finally, two interesting case reports showing 
the importance of ICGA in choroidopathies 
conclude the series of seven articles related to 
the SOIE. Papadia and Herbort6 present a case 
where central serous chorioretinopathy was 
mistaken for an inflammatory chorioretinopathy 
and treated with corticosteroids leading to a 
deleterious evolution. If ICGA signs had been 
taken into account, the diagnosis could have 
been made early without the consequences. 
Darugar and colleagues7 from the Pitié-
Salpétrière hospital in Paris, housing one of the 
most important uveitis departments in Western 
Europe, present a case with typical clinical and 
ICGA findings of APMPPE. They stress the 
role of the choriocapillaris in the pathogenesis 
of APMPPE and remind us that a large range 
of differential diagnoses has to be considered 
before the condition can be termed idiopathic. 
The collaborative effort between our two 
medical backgrounds resulted in the present 
issue of the JOVR that will hopefully interest 
ophthalmologists in both settings and will lead 
to closer contacts and better mutual appreciation 
and understanding.
We truly hope the reader will enjoy this 
special JOVR issue on uveitis and intraocular 
inflammation.
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